| 000 | 01656cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030525.0 | ||
| 008 | 111207s2011 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.04.Ph.D.2011.Ol.A | ||
| 100 | 0 | _aOla Mohamad Elfarargy | |
| 245 | 1 | 0 |
_aAssessment of bisphosphonates use as adjuvant therapy in breast cancer / _cOla Mohamad Elfarargy ; Supervised Zekri Khalid Zekri , Nadia Iskandar Zakhary , Heba M. Rabie Elzawahry |
| 246 | 1 | 5 | _aتقييم استخدام عقار البيسفسفونات كعلاج تحفظى فى حالات سرطان الثدى |
| 260 |
_aCairo : _bOla Mohamad Elfarargy , _c2011 |
||
| 300 |
_a168 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical | ||
| 520 | _aBreast cancer is the most common cancer in female worldwide and considered commonest cause of cancer related death in female. Inspite of an increasing incidence, breast cancer mortality has been declining. This is the combined result of better education, widespread screening programs and more efficacious adjuvant treatments | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAdjuvant therapy | |
| 653 | 4 | _aBisphosphonates | |
| 653 | 4 | _aBreast cancer | |
| 700 | 0 |
_aHeba Mohamed Rabie Elzawahry , _eSupervisor |
|
| 700 | 0 |
_aNadia Iskandar Zakhary , _eSupervisor |
|
| 700 | 0 |
_aZekri Khalid Zekri , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c36516 _d36516 |
||